Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
|Articles|December 17, 2011
Video: Stimulants in Alzheimer Dementia: What Role in Early Disease?
Author(s)Anton Porsteinsson, MD
Listen
0:00 / 0:00
Can stimulants increase function in people with early stage Alzheimer disease? Here, Anton Porsteinsson, MD, discusses the pros and cons.
Advertisement
Can stimulants increase function in people with early stage Alzheimer disease? Here, Anton Porsteinsson, MD, discusses the pros and cons.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5